# Bio-SF

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bio-sf

- Industry: Biotechnology
- Headquarters: Changshu, China
- Website: www.bio-safety.com.cn
- Total disclosed funding: $2.1M
- Latest round: Series A (Oct 16, 2025)
- Investors on record: 5

## About

Established in 2020 and based in Changshu, China, Jiangsu Bio-SF Medical Technology Co., Ltd. focuses on evaluating the safety of medical products. In October 2025, Bio-SF raised CNY 15 million in Series A funding from new investor Kushan Industrial Research Institute Management.
Bio-SF specializes in the evaluation of the efficacy and safety of medical devices, biomaterials, pharmaceuticals, and combination products. The company operates a comprehensive suite of services tailored to meet the rigorous standards of medical and clinical research, primarily through its state-of-the-art laboratory facilities, which span 4,114 square meters. Key offerings include an animal testing center, a testing center, and a training center, designed to support the development and regulatory approval of medical products. The client base primarily consists of pharmaceutical companies, medical device manufacturers, and research institutions seeking to ensure compliance with international safety standards. The company serves both domestic and international markets, providing essential services to clients in North America, Europe, and Asia.
Bio-SF generates revenue through a structured transaction model that encompasses direct services to clients within the medical and pharmaceutical industries. The firm engages in business-to-business (B2B) interactions, providing specialized testing and evaluation services on a contractual basis. Clients may enter into agreements for comprehensive testing packages, which may include a series of assessments tailored to specific regulatory requirements. The company’s flagship services are positioned as critical components in the product development lifecycle, and pricing structures are determined based on the complexity and scope of services rendered. Revenue is derived from these service contracts, contributing to a stable financial foundation for the company.

## Funding rounds

- Series A, Oct 16, 2025, $2.1M — Kushan Industrial Research Institute Management
- Angel, May 21, 2023 — Beijing Haina Yourong Capital, Huiyi Capital, Changshu Dakeyuan Entrepreneurship Investment, Yinji Venture Capital

## Investors

- Beijing Haina Yourong Capital (https://capitalatlas.ai/funds/beijing-haina-yourong-capital) — Angel
- Huiyi Capital (https://capitalatlas.ai/funds/huiyi-capital) — Angel
- Changshu Dakeyuan Entrepreneurship Investment — Angel
- Yinji Venture Capital — Angel
- Kushan Industrial Research Institute Management (https://capitalatlas.ai/funds/kushan-industrial-research-institute-management) — Series A